Impax Laboratories Price Target Raised to $35.00 at WallachBeth Capital (IPXL)
Research analysts at WallachBeth Capital upped their price target on shares of Impax Laboratories (NASDAQ:IPXL) from $32.00 to $35.00 in a report released on Thursday. The firm currently has a “buy” rating on the stock. WallachBeth Capital’s price objective would indicate a potential upside of 14.68% from the stock’s previous close.
A number of other analysts have also recently weighed in on IPXL. Analysts at Wells Fargo & Co. initiated coverage on shares of Impax Laboratories in a research note on Tuesday, June 10th. They set a “market perform” rating on the stock. Separately, analysts at Buckingham Research upgraded shares of Impax Laboratories from an “underperform” rating to a “neutral” rating in a research note on Wednesday, May 7th. They now have a $26.00 price target on the stock, up previously from $15.00. Finally, analysts at Guggenheim raised their price target on shares of Impax Laboratories from $30.00 to $32.00 in a research note on Friday, May 2nd. Seven research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $26.70.
Impax Laboratories (NASDAQ:IPXL) opened at 30.52 on Thursday. Impax Laboratories has a 1-year low of $19.39 and a 1-year high of $31.01. The stock has a 50-day moving average of $28.22 and a 200-day moving average of $25.91. The company has a market cap of $2.074 billion and a P/E ratio of 1397.27.
Impax Laboratories (NASDAQ:IPXL) last released its earnings data on Thursday, May 1st. The company reported $0.24 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.05 by $0.19. The company had revenue of $118.70 million for the quarter, compared to the consensus estimate of $97.80 million. During the same quarter in the prior year, the company posted $0.37 earnings per share. The company’s quarterly revenue was down 20.1% on a year-over-year basis. On average, analysts predict that Impax Laboratories will post $0.88 earnings per share for the current fiscal year.
Impax Laboratories Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products, referred to as generics, in addition to the development and marketing of branded products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.